Atossa Therapeutics
ATOS
9 hedge funds and large institutions have $207K invested in Atossa Therapeutics in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
36% less funds holding
Funds holding: 14 → 9 (-5)
54% less capital invested
Capital invested by funds: $446K → $207K (-$239K)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$60K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$31.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$16.8K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$4.8K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$600 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$47.4K |
| 2 |
GBBWRPM
Genovese Burford & Brothers Wealth & Retirement Plan Management
Sacramento,
California
|
-$45K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$24K |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$13K |
| 5 |
Goldman Sachs
New York
|
-$12K |
ATOS Hedge Fund Activity: Q3 2016 in Review
9 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q3 2016, worth a combined $207K — down 54% from $446K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ATOS and 2 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $60K. The largest seller was Vanguard Group, cutting an estimated $47.4K.
- 9 institutional investors held Atossa Therapeutics (ATOS) as of Q3 2016, down from 14 in Q2 2016.
- Funds reported $207K of Atossa Therapeutics stock for Q3 2016, down 54% quarter-over-quarter.
- 2 funds opened new Atossa Therapeutics positions in Q3 2016 and 7 closed out, a net change of -5 holders.
- The largest Atossa Therapeutics buyer in Q3 2016 was Renaissance Technologies, an estimated $60K added.
- The largest Atossa Therapeutics seller in Q3 2016 was Vanguard Group, an estimated $47.4K sold.
Based on aggregated 13F filings for Q3 2016.